LifeTech Capital Reiterates Neutral Rating on Echo Therapeutics Following Q2 Results
August 19, 2013 at 12:12 PM EDT
In a report published Monday, LifeTech Capital analyst Stephen M. Dunn reiterated a Neutral rating on Echo Therapeutics (NASDAQ: ECTE ). In the report, LifeTech Capital noted, “Maintaining Neutral Rating: We continue to believe Echo's Symphony tCGM remains a world-class technology trapped under a cloud of management's failure to unlock
